Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9998266 | 0.91 | ALDH1A1 (0.34) | KMT2AMEN1ALDH1A1BRD4PKM | |
| SCHEMBL15333396 | 0.90 | ALDH1A1 (0.38) | KMT2AMEN1ALDH1A1GSK3BPOLB | |
| SCHEMBL1206417 | 0.87 | MEN1 (0.32) | KMT2AMEN1ALDH1A1BRD4 | |
| SCHEMBL2497098 | 0.83 | ADORA2A (0.37) | KMT2AMEN1ALDH1A1PDE4AADORA2A | |
| SCHEMBL1206348 | 0.80 | ALDH1A1 (0.43) | KMT2AMEN1ALDH1A1PDE4AADORA2A | |
| SCHEMBL19810013 | 0.79 | TBXAS1 (0.39) | KMT2AMEN1CNR1CNR2CYP1A2 | |
| SCHEMBL19810012 | 0.79 | TBXAS1 (0.39) | KMT2AMEN1CNR1CNR2CYP1A2 | |
| SCHEMBL14901265 | 0.79 | DUT (0.42) | KMT2AMEN1 | |
| SCHEMBL21167268 | 0.77 | MEN1 (0.30) | KMT2AMEN1 | |
| SCHEMBL27482509 | 0.77 | HTT (0.37) | KMT2AMEN1ALDH1A1ADORA2BPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545668-B2 | Cyclic amine derivative as agent for promoting advillin function, and novel cyclic amine derivative and pharmaceutical use thereof | TORAY INDUSTRIES, INC. (JP) | 2026-02-10 | — | — | US | disclosed |
| EP-3777858-B1 | AGENT FOR INHIBITING RISE IN INTRANEURONAL CALCIUM CONCENTRATION | TORAY INDUSTRIES (JP) | 2025-04-02 | — | — | EP | disclosed |
| CN-111902143-B | Inhibitors of calcium concentration increase in nerve cells | 东丽株式会社 | 2024-01-02 | — | — | CN | disclosed |
| CN-113831337-B | GLP-1 receptor agonist, and pharmaceutical composition and use thereof | 广州市恒诺康医药科技有限公司 | 2023-03-24 | — | — | CN | disclosed |
| US-20220409589-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2022-12-29 | — | — | US | disclosed |
| US-11510914-B2 | Agent for inhibiting rise in intraneuronal calcium concentration | TORAY INDUSTRIES, INC. (JP) | 2022-11-29 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-115124512-A | Cyclic amine derivative and medical use thereof | 东丽株式会社 | 2022-09-30 | — | — | CN | disclosed |
| US-20220081431-A1 | CYCLIC AMINE DERIVATIVE AS AGENT FOR PROMOTING ADVILLIN FUNCTION, AND NOVEL CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2022-03-17 | — | — | US | disclosed |
| US-20220081431-A1 | CYCLIC AMINE DERIVATIVE AS AGENT FOR PROMOTING ADVILLIN FUNCTION, AND NOVEL CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2022-03-17 | — | — | US | disclosed |
| EP-1465889-A4 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC (CA) | 2008-05-14 | — | — | EP | disclosed |
| US-7354934-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2008-04-08 | — | — | US | disclosed |
| US-7354932-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2008-04-08 | — | — | US | disclosed |
| US-20060100240-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2006-05-11 | — | — | US | disclosed |
| EP-1628533-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004106493-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2004-12-09 | — | — | WO | disclosed |
| EP-1465889-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | AnorMED Inc. (CA) | 2004-10-13 | — | — | EP | disclosed |
| US-20040019058-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2004-01-29 | — | — | US | disclosed |
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2003-11-27 | — | — | US | disclosed |
| WO-2003055876-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545668-B2 | Cyclic amine derivative as agent for promoting advillin function, and novel cyclic amine derivative and pharmaceutical use thereof | SSB, TLR9, C5AR2 | KMT2A 2657/4885MEN1 2154/4885ALDH1A1 2744/4885 |
| US-11510914-B2 | Agent for inhibiting rise in intraneuronal calcium concentration | ITPR2, ATP2A2, ORAI1 | KMT2A 4251/4885MEN1 255/4885ALDH1A1 4246/4885 |
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | KMT2A 3464/4885MEN1 3210/4885ALDH1A1 3305/4885 |
| US-20060100240-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | KMT2A 3464/4885MEN1 3210/4885ALDH1A1 3305/4885 |
| US-20220409589-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CCR5, CXCR4, CXCR3 | KMT2A 3464/4885MEN1 3210/4885ALDH1A1 3305/4885 |
| US-20040019058-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | KMT2A 3464/4885MEN1 3210/4885ALDH1A1 3305/4885 |
| US-20220081431-A1 | CYCLIC AMINE DERIVATIVE AS AGENT FOR PROMOTING ADVILLIN FUNCTION, AND NOVEL CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | ADCY10, ADCK5, AANAT | KMT2A 4194/4885MEN1 2501/4885ALDH1A1 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.